# US 2016/0250221 A1 · Inhibitors of fapp2 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250221 A1
- Document ID: US20160250221A1
- Status: Published application
- Kind: A1
- Application number: 14/907,172
- Filed: 2014-07-25
- Published: 2016-09-01
- Earliest claimed: 2013-07-25
- Assignees: Fondazione Telethon
- Applicants: Fondazione Telethon
- Inventors: Raffaele LA MONTAGNA; Maria Antonietta DE MATTEIS; Giovanni D'ANGELO
- Web page: https://patentgrep.com/patent/US20160250221A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides methods and compositions for reducing globotriaosylceramide (Gb3) accumulation and treating diseases, disorders or conditions associated with Gb3 accumulation based on inhibitors of phosphatidylinositol-4-phosphate adaptor-2 (FAPP2), including interfering oligonucleotides, for example, siRNAs, and small molecule compounds based inhibitors. The present invention is particularly useful in treating Fabry disease and other sphingolipidoses relating to sphingolipid metabolism, such as Gaucher's disease.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

A method of reducing globotrioaosylceramide (Gb3) accumulation in a cell, comprising administering to a cell having or susceptible to Gb3 accumulation an effective amount of an inhibitor of phosphatidylinositol-4-phosphate adaptor-2 (FAPP2).

### Claim 4

A method of treating a disease, disorder or condition associated with globotrioaosylceramide (Gb3) accumulation, comprising administering to a subject in need of treatment an effective amount of an inhibitor of phosphatidylinositol-4-phosphate adaptor-2 (FAPP2).

### Claim 5 (depends on 3)

The method of claim 3, wherein the cell is a mammalian cell.

### Claim 6 (depends on 3)

The method of claim 3, wherein the cell is a cultured cell.

### Claim 7 (depends on 3)

The method of claim 3, wherein the cell is a cell of an organism.

### Claim 8 (depends on 4)

The method of claim 4, wherein said inhibitor is an aryl glucoside compound comprising a glycosidic linkage, or an interfering oligonucleotide.

### Claim 9 (depends on 8)

The method of claim 8, wherein said aryl glucoside compound is a C-aryl glucoside compound or an O-aryl glucoside compound.

### Claim 10 (depends on 8)

The method of claim 8, wherein the aryl glucoside compound has a structure of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Q is a monosaccharide or modified monosaccharide;
A1 is phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;
A2 is phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;
L1 is a covalent bond, or a C1-4 bivalent straight or branched hydrocarbon chain, wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O)2—, —S(O)2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —S(O)2—;
L2 is a covalent bond or —O—;
each R1 is independently halogen, —CN, —R; —OR; —SR; —N(R)2; —N(R)C(O)R; —C(O)N(R)2; —N(R)C(O)N(R)2; —N(R)C(O)OR; —OC(O)N(R)2; —N(R)S(O)2R; —S(O)2N(R)2; —OC(O)OR; —C(O)R; —OC(O)R; —C(O)OR; —S(O)R; —S(O)2R; or Cy;
each R2 is independently halogen, —CN, —R, —OR, —SR, —N(R)2, —N(R)C(O)R, —C(O)N(R)2, —N(R)C(O)N(R)2, —N(R)C(O)OR, —OC(O)N(R)2, —N(R)SO2R, —S(O)2N(R)2, —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, or —S(O)2R;
Cy is a ring, substituted with p instances of R3; wherein said ring is selected from the group consisting of a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aromatic carbocyclic ring; a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R is independently hydrogen, deuterium, or an optionally substituted group selected from C1-6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aromatic carbocyclic ring; a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R3 is independently halogen, —R, —CN, —OR, —SR, —N(R)2, —N(R)C(O)R, —C(O)N(R)2, —C(O)N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(O)OR, —OC(O)N(R)2, —N(R)S(O)2R, —S(O)2N(R)2, —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, —S(O)2R, —B(OR)2, or an optionally substituted ring selected from phenyl and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
p is 1-5; x is 0-5; and y is 0-4.

### Claim 11 (depends on 8)

The method of claim 8, wherein the aryl glucoside compound has a structure of formula II-a or II-b:
or a pharmaceutically acceptable salt thereof, wherein:
A1 is phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;
each R1 is independently halogen, —CN, —R; —OR; —SR; —N(R)2; —N(R)C(O)R; —C(O)N(R)2; —N(R)C(O)N(R)2; —N(R)C(O)OR; —OC(O)N(R)2; —N(R)S(O)2R; —S(O)2N(R)2; —OC(O)OR; —C(O)R; —OC(O)R; —C(O)OR; —S(O)R; —S(O)2R; or Cy;
each R2 is independently halogen, —CN, —R, —OR, —SR, —N(R)2, —N(R)C(O)R, —C(O)N(R)2, —N(R)C(O)N(R)2, —N(R)C(O)OR, —OC(O)N(R)2, —N(R)SO2R, —S(O)2N(R)2, —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, or —S(O)2R;
Cy is a ring, substituted with p instances of R3; wherein said ring is selected from the group consisting of a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aromatic carbocyclic ring; a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R is independently hydrogen, deuterium, or an optionally substituted group selected from C1-6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aromatic carbocyclic ring; a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R3 is independently halogen, —R, —CN, —OR, —SR, —N(R)2, —N(R)C(O)R, —C(O)N(R)2, —C(O)N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(O)OR, —OC(O)N(R)2, —N(R)S(O)2R, —S(O)2N(R)2, —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, —S(O)2R, —B(OR)2, or an optionally substituted ring selected from phenyl and 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
p is 1-5; x is 0-5; and y is 0-4.

### Claim 12 (depends on 8)

The method of claim 8, wherein the aryl glucoside compound has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the aryl glucoside compound has a structure of
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 8)

The method of claim 8, wherein the aryl glucoside compound has a structure selected from the group consisting of:
or pharmaceutically acceptable salts thereof,
wherein each R4 can be the same or different and is selected from the group consisting of H and -L2-Q, wherein Q is a monosaccharide or modified monosaccharide and L2 is a covalent bond or —O—, provided that the aryl glucoside compound includes at least one glycosidic linkage.

### Claim 15 (depends on 14)

The method of claim 14, wherein the aryl glucoside compound comprises one glycosidic linkage.

### Claim 16 (depends on 4)

The inhibitor or the method of claim 4, wherein said inhibitor has a structure selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 17 (depends on 4)

The inhibitor or the method of claim 4, wherein said inhibitor is an interfering oligonucleotide that inhibits expression of phosphatidylinositol-4-phosphate adaptor-2 (FAPP2).

### Claim 18 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide is an siRNA or shRNA.

### Claim 19 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide has a sequence that is at least 80% identical to the reverse complement of a continuous sequence of the human FAPP2 gene or a messenger RNA (mRNA) of FAPP2.

### Claim 20 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide has a sequence that is at least 90% identical to the reverse complement of a continuous sequence of the human FAPP2 gene or an messenger RNA (mRNA) of FAPP2.

### Claim 21 (depends on 19)

The method of claim 19, wherein the interfering oligonucleotide has a sequence that is identical to the reverse complement of a continuous sequence of the human FAPP2 gene or an messenger RNA (mRNA) of FAPP2.

### Claim 22 (depends on 17)

The method of claim 17, wherein the mRNA of FAPP2 comprises one of FAPP2 mRNA Isoform 1, FAPP2 mRNA Isoform 2, and FAPP2 mRNA Isoform 3.

### Claim 23 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide is less than 25 nucleotides in length.

### Claim 24 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide is 16-22 nucleotides in length.

### Claim 25 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide is an siRNA or shRNA having a sequence selected from:
[FAPP2.1]
SEQ ID No. 3
GAGAUAGACUGCAGCAUAU[dT][dT]
[FAPP2.2]
SEQ ID No. 4
GAAUUGAUGUGGGAACUUU[dT][dT]
[FAPP2.3]
SEQ ID No. 5
GAAAUCAACCUGUAAUACU[dT][dT]
[FAPP2.4]
SEQ ID No. 6
CCUAAGAAAUCCAACAGAA[dT][dT]
[sh FAPP2.1]
SEQ ID No. 7
CTCTTGTGGCTGAAGAGAGGTCTCAAATT;
[shFAPP2.2]
SEQ ID No. 8
TTGGCAGCCTCGATGGTTCCTTCTCTGTG;
[shFAPP2.3]-
SEQ ID No. 9
CAGTCTGGATCAGACTCAAGTTGCTCTCC;
and/or
[shFAPP2.4]
SEQ ID No. 10
TCCTGTTAAGATGGATCTTGTTGGAAATA.

### Claim 26 (depends on 17)

The method of claim 17, wherein the interfering oligonucleotide comprises at least one chemical modification.

### Claim 27 (depends on 26)

The method of claim 26, wherein the at least one chemical modification is selected from the group consisting of conformationary constraint nucleotide analogue, 2′O-methyl modification, phosphorothioate linkage, and combination thereof.

### Claim 28 (depends on 4)

The method of claim 4, wherein the disease, disorder or condition is Fabry disease or a sphingolipidose such as Gaucher's disease.

### Claim 29 (depends on 4)

The inhibitor or the method of claim 4, wherein the disease, disorder or condition is Fabry disease.

### Claim 30

(canceled)

### Claim 31

A method to identify a phosphatidylinositol-4-phosphate adaptor-2 (FAPP2) inhibitor comprising:
mixing acceptor vesicles, donor vesicles containing a fluorescent-labeled moiety, a quencher, and recombinant FAPP2 protein to form a mixture; and
measuring the emission intensity of the mixture either in the presence or in the absence of an agent, wherein if the emission intensity is decreased in the presence of the agent, said agent is identified as a FAPP2 inhibitor.

### Claim 32 (depends on 31)

The method according to claim 31 wherein the recombinant FAPP2 protein is FAPP2-GLTP-C212 or FAPP2 Full-Length (FL).

### Claim 33 (depends on 31)

The method according to claim 31, wherein the acceptor vesicles contain 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
